subscribeSubscribe
FDA Confirms Paragraph IV Patent Litigation for Ubrogepant Tablets

FDA Confirms Paragraph IV Patent Litigation for Ubrogepant Tablets
FDA
27 Feb 2024
Share Share
AbbVie`s Ubrelvy significantly cuts headache pain if taken during prodrome

AbbVie`s Ubrelvy significantly cuts headache pain if taken during prodrome
PRESS RELEASE
17 Nov 2023
Share Share
AbbVie Announces Serena Williams as Spokesperson to Shed Light on UBRELVY®

AbbVie Announces Serena Williams as Spokesperson to Shed Light on UBRELVY®
PRNEWSWIRE
04 Aug 2020
Share Share
With DEA scheduling, Lilly`s Reyvow cleared for launch

With DEA scheduling, Lilly`s Reyvow cleared for launch
Eric Sagonowsky FIERCE PHARMA
31 Jan 2020
Share Share
Biohaven celebrates PhII/III win for intranasal CGRP migraine drug with Allergan

Biohaven celebrates PhII/III win for intranasal CGRP migraine drug with Allergan
Amber Tong ENDPT NEWS
17 Dec 2019
Share Share
Allergan`s acute migraine therapy ubrogepant shows strength at Phase 3

Allergan`s acute migraine therapy ubrogepant shows strength at Phase 3
PHARMAFILE
20 Nov 2019
Share Share
ICER Releases Draft Evidence Report on Acute Migraine Therapies

ICER Releases Draft Evidence Report on Acute Migraine Therapies
ICER
08 Nov 2019
Share Share
Biohaven, sporting new data, moves closer to CGRP finish line—and maybe M&A

Biohaven, sporting new data, moves closer to CGRP finish line—and maybe M&A
Angus Liu FIERCE PHARMA
11 Jul 2019
Share Share
Allergan Announces FDA Acceptance of NDA for Ubrogepant

Allergan Announces FDA Acceptance of NDA for Ubrogepant
PR NEWSWIRE
11 Mar 2019
Share Share
Eyeing blockbuster migraine market,Allergan unloads +ve PhIII results ubrogepant

Eyeing blockbuster migraine market,Allergan unloads +ve PhIII results ubrogepant
B. Meiling ENDPTS
28 Apr 2018
Share Share